GSK · story · 28 October
GSK · 7 headlines from 7 outlets, on 28 October 2026.
WSJ and others report GSK expects its clinical cancer pipeline to nearly double next year after dealmaking.
The story's tone is the average of its headlines' own scores. Each score rates how good or bad the news was for the company, from −10 (clearly bad) to +10 (clearly good). 0 is neutral, and anything beyond ±6 is strong and rare. It rates the coverage, not the share price.
Average tone of each outlet's headlines in this story, −10 to +10. Impact = headlines × strength of tone.
Reuters is the largest at 9.2, ahead of WSJ (9.2). Seeking Alpha is the smallest at 7.5.
Source: MarketFrame news analysis
| outlet | Average tone |
|---|---|
| Reuters | 9.2 |
| WSJ | 9.2 |
| Quartz | 8.3 |
| Investing.com | 8.3 |
| TradingView | 8.3 |
| Seeking Alpha | 7.5 |
| TipRanks | 7.5 |
| Outlet | Headlines | Average tone |
|---|---|---|
| Reuters | 1 | +9.2 |
| WSJ | 1 | +9.2 |
| Quartz | 1 | +8.3 |
| Investing.com | 1 | +8.3 |
| TradingView | 1 | +8.3 |
| Seeking Alpha | 1 | +7.5 |
| TipRanks | 1 | +7.5 |
One or two headlines is not a lean: read these as how this story was told, not as a verdict on the outlet.
| Tone | What the article reported, and why it scored that way |
|---|---|
| +9.2 | Company expects far larger number of cancer programmes in trials. |
| +9.2 | Acquisitions and licensing set to nearly double cancer pipeline. |
| +8.3 | Company anticipates a much bigger cancer development portfolio. |
| +8.3 | Dealmaking expected to expand cancer trial pipeline significantly. |
| +8.3 | Newspaper report of planned doubling of cancer trials. |
| +7.5 | Strategic emphasis on expanding cancer business. |
| +7.5 | Report says re-entry into cancer treatment is yielding results. |
A short, free morning email on how the news treated GSK: the tone, the stories behind it, and when coverage starts to turn. Launching soon; one click to unsubscribe.